-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the main challenge of colorectal cancer (CRC) treatment is to be able to detect the recurrence of patients after surgery in time, and to identify patients who are at high risk of recurrence after surgery and adjuvant therapy (ACT).
At present, the main challenge of colorectal cancer (CRC) treatment is to be able to detect the recurrence of patients after surgery in time, and to identify patients who are at high risk of recurrence after surgery and adjuvant therapy (ACT).
ASCO ctDNA test to evaluate colorectal cancer
The purpose of this prospective multi-center study is to determine whether the use of ctDNA testing after multiple operations can identify high-risk relapsed patients, detect relapse earlier than standard radionuclide imaging, and evaluate adjuvant therapy.
This cohort study included 265 patients with clinical stage I-III colorectal cancer, and it is also the largest cohort evaluated for ctDNA testing to date.
Adjuvant Therapy (ACT)
Plasma samples were collected at different time points (n = 1503), and the median follow-up time was 28.
Whole-exome sequencing of each tumor and matched germline DNA
Before ACT treatment, postoperative ctDNA testing was performed on 218 patients, of which 9.
Carcinoembryonic antigen ( CEA ) and ctDNA were evaluated and compared to 155 postoperative patients .
Carcinoembryonic antigen ( CEA ) The definition of CEA recurrence-free survival (RFS) refers to the time from initial surgery to the earliest evidence of recurrence.
Effective treatment can cure some MRD-positive patients.
In general, the significance of longitudinal ctDNA analysis: 1.
Tenna V Henriksen, Noelia Tarazona, Thomas Reinert, et al.
Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.
2021 ASCO GI, 11abs.
Leave a message here
